Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...
Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.
Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharma focused on developing cystic fibrosis therapies, opened well above its initial public offering price on Friday in its first trading ...
Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback